Allscripts (MDRX) Tops Q2 EPS by 1c, Affirms FY Guidance

Allscripts (NASDAQ: MDRX) reported Q2 EPS of $0.12, $0.01 better than the analyst estimate of $0.11. Revenue for the quarter came in at $351.7 million versus the consensus estimate of $348.48 million.Allscripts reaffirmed FY2015 guidance.

2015 Guidance Affirmed

Allscripts reaffirmed its prior financial guidance for 2015:

• Revenue between $1.40 billion and $1.43 billion;
• Adjusted EBITDA between $230 million and $250 million; and
• Non-GAAP earnings per share between $0.42 and $0.50 per diluted share.

For earnings history and earnings-related data on Allscripts (MDRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Piper Sandler on Fervo Energy (FRVO): 'Capital Access Supports Potential Upside'
• Deutsche Bank Starts DexCom (DXCM) at Buy